AG˹ٷ

STOCK TITAN

[Form 4] Verastem, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Verastem, Inc. (VSTM) � Form 4 insider transaction summary

Chief Financial Officer Daniel Calkins filed a Form 4 reporting two open-market sales of Verastem common stock:

  • 06/20/2025: 4,110 shares sold at $5.13 per share.
  • 06/23/2025: 25 shares sold at $4.71 per share.

The filing explains that the transactions were executed solely to cover statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs). No derivative securities were involved in this report.

Following the sales, Calkins� direct beneficial ownership stands at 109,945 common shares. The disposition represents roughly 3.6 % of his previously reported direct holdings, leaving the executive with a substantial equity position that continues to align his interests with shareholders.

No additional purchases, option exercises, or new awards were disclosed, and there is no indication of a 10b5-1 trading plan for these transactions. Because the sales were relatively small and explained as tax-related, the market impact is expected to be limited; however, investors often track insider activity for sentiment cues, and any sale by a senior officer can attract attention.

Verastem, Inc. (VSTM) � Riepilogo delle transazioni interne Form 4

Il Chief Financial Officer Daniel Calkins ha presentato un modulo Form 4 che segnala due vendite sul mercato aperto di azioni ordinarie Verastem:

  • 20/06/2025: 4.110 azioni vendute a 5,13 $ per azione.
  • 23/06/2025: 25 azioni vendute a 4,71 $ per azione.

La comunicazione spiega che le transazioni sono state eseguite esclusivamente per coprire gli obblighi fiscali derivanti dal consolidamento delle azioni vincolate (RSU) precedentemente assegnate. Non sono stati coinvolti strumenti derivati in questo rapporto.

Dopo le vendite, la proprietà diretta di Calkins ammonta a 109.945 azioni ordinarie. La cessione rappresenta circa il 3,6% delle sue partecipazioni dirette precedentemente dichiarate, lasciando l’esecutivo con una posizione azionaria significativa che continua ad allineare i suoi interessi con quelli degli azionisti.

Non sono stati comunicati ulteriori acquisti, esercizi di opzioni o nuove assegnazioni, né vi è indicazione di un piano di trading 10b5-1 per queste transazioni. Poiché le vendite sono state relativamente modeste e motivate da ragioni fiscali, l’impatto sul mercato è previsto limitato; tuttavia, gli investitori spesso monitorano l’attività degli insider per cogliere segnali di sentiment, e qualsiasi vendita da parte di un dirigente senior può attirare attenzione.

Verastem, Inc. (VSTM) � Resumen de transacciones internas Form 4

El Director Financiero Daniel Calkins presentó un Formulario 4 reportando dos ventas en el mercado abierto de acciones comunes de Verastem:

  • 20/06/2025: 4,110 acciones vendidas a $5.13 por acción.
  • 23/06/2025: 25 acciones vendidas a $4.71 por acción.

La presentación explica que las transacciones se realizaron únicamente para cubrir obligaciones fiscales legales derivadas de la consolidación de unidades restringidas de acciones (RSUs) previamente otorgadas. No se involucraron valores derivados en este informe.

Tras las ventas, la propiedad directa de Calkins asciende a 109,945 acciones comunes. La disposición representa aproximadamente el 3.6% de sus participaciones directas previamente reportadas, dejando al ejecutivo con una posición accionaria significativa que sigue alineando sus intereses con los de los accionistas.

No se divulgaron compras adicionales, ejercicios de opciones ni nuevas adjudicaciones, y no hay indicios de un plan de trading 10b5-1 para estas transacciones. Debido a que las ventas fueron relativamente pequeñas y se explicaron como relacionadas con impuestos, se espera que el impacto en el mercado sea limitado; sin embargo, los inversores suelen seguir la actividad de los insiders para obtener señales de sentimiento, y cualquier venta por parte de un alto ejecutivo puede atraer atención.

Verastem, Inc. (VSTM) � Form 4 내부� 거래 요약

최고재무책임�(CFO) 다니� 콜킨스가 Verastem 보통주에 대� � 건의 공개시장 매도� 보고하는 Form 4� 제출했습니다:

  • 2025� 6� 20�: 주당 $5.13� 4,110� 매도.
  • 2025� 6� 23�: 주당 $4.71� 25� 매도.

� 제출 서류� 이전� 부여된 제한 주식 단위(RSU)� 권리 확정으로 인해 발생� 법적 세금 원천징수 의무� 충당하기 위해 거래가 이루어졌음을 설명합니�. � 보고서에� 파생 증권� 포함되지 않았습니�.

매도 � 콜킨스의 직접 소유 지분은 109,945� 보통�입니�. 이번 매도� 이전� 보고� 직접 보유 지분의 � 3.6%� 해당하며, 경영진은 상당� 지분을 유지하며 주주들과 이해관계를 계속 일치시키� 있습니다.

추가 매수, 옵션 행사 또는 신규 수여� 공개되지 않았으며, � 거래� 대� 10b5-1 거래 계획� 없습니다. 매도가 비교� 적고 세금 관련임� 감안� � 시장 영향은 제한적일 것으� 예상되나, 투자자들은 종종 내부� 활동� 감정 신호� 주시하며, 고위 임원� 매도� 주목� 받을 � 있습니다.

Verastem, Inc. (VSTM) � Résumé des transactions d’initiés Formulaire 4

Le directeur financier Daniel Calkins a déposé un formulaire 4 rapportant deux ventes sur le marché libre d’actions ordinaires Verastem :

  • 20/06/2025 : 4 110 actions vendues à 5,13 $ par action.
  • 23/06/2025 : 25 actions vendues à 4,71 $ par action.

Le dépôt explique que ces transactions ont été effectuées uniquement pour couvrir les obligations fiscales légales déclenchées par l’acquisition des unités d’actions restreintes (RSU) précédemment attribuées. Aucun titre dérivé n’est concerné par ce rapport.

Après ces ventes, la propriété directe de M. Calkins s’élève à 109 945 actions ordinaires. La cession représente environ 3,6 % de ses avoirs directs précédemment déclarés, laissant le dirigeant avec une position significative en actions, ce qui continue d’aligner ses intérêts avec ceux des actionnaires.

Aucun achat supplémentaire, exercice d’options ou nouvelle attribution n’a été divulgué, et il n’y a aucune indication d’un plan de trading 10b5-1 pour ces transactions. Étant donné que les ventes sont relativement modestes et expliquées comme liées à des obligations fiscales, l’impact sur le marché devrait être limité ; toutefois, les investisseurs suivent souvent l’activité des initiés pour détecter des signaux de sentiment, et toute vente par un cadre supérieur peut attirer l’attention.

Verastem, Inc. (VSTM) � Zusammenfassung der Insider-Transaktionen Form 4

Finanzvorstand Daniel Calkins reichte ein Form 4 ein, das zwei Verkäufe von Verastem-Stammaktien am offenen Markt meldet:

  • 20.06.2025: 4.110 Aktien zu je 5,13 $ verkauft.
  • 23.06.2025: 25 Aktien zu je 4,71 $ verkauft.

Die Meldung erklärt, dass die Transaktionen ausschließlich zur Deckung gesetzlicher Steuerabzugsverpflichtungen erfolgten, die durch das Vesting zuvor gewährter Restricted Stock Units (RSUs) ausgelöst wurden. Es waren keine Derivate in diesem Bericht enthalten.

Nach den Verkäufen hält Calkins direkt 109.945 Stammaktien. Die Veräußerung entspricht etwa 3,6 % seiner zuvor gemeldeten direkten Beteiligungen und hinterlässt den Manager mit einer erheblichen Aktienposition, die seine Interessen weiterhin mit denen der Aktionäre in Einklang bringt.

Es wurden keine weiteren Käufe, Ausübungen von Optionen oder neue Zuteilungen bekannt gegeben, und es gibt keinen Hinweis auf einen 10b5-1-Handelsplan für diese Transaktionen. Da die Verkäufe relativ gering und steuerbedingt waren, wird die Marktwirkung als begrenzt eingeschätzt; dennoch verfolgen Investoren Insider-Aktivitäten oft als Stimmungsindikator, und jeder Verkauf durch einen leitenden Angestellten kann Aufmerksamkeit erregen.

Positive
  • CFO retains 109,945 shares, preserving meaningful insider alignment with shareholders.
  • Sale was explicitly linked to tax withholding on RSU vesting, limiting negative signaling.
Negative
  • Insider sale, even if small, can be interpreted by some investors as a bearish sentiment indicator.

Insights

TL;DR: Small CFO sale, tax-motivated, negligible strategic signal.

The aggregate sale of 4,135 shares (~US$21k) is immaterial to Verastem’s float and represents a modest 3-4 % trim of the CFO’s stake. The filing specifically states the sales were to satisfy withholding on RSU vesting, a routine administrative action that does not typically reflect an adverse view of future fundamentals. Post-sale ownership of ~110k shares maintains meaningful skin-in-the-game. I view the disclosure as neutral from a valuation standpoint; no operational or guidance information is included, and the transaction size is too small to alter supply-demand dynamics.

TL;DR: Insider disposition is procedural; governance risk unchanged.

Rule 16b filings like this are common when RSUs vest. The sale was not executed under a Rule 10b5-1 plan, but the stated purpose—covering tax—is credible. Remaining ownership suggests continuing alignment, and no red flags (e.g., multiple executives selling, accelerated vesting) are present. Accordingly, I classify the event as not impactful on governance risk or insider confidence metrics.

Verastem, Inc. (VSTM) � Riepilogo delle transazioni interne Form 4

Il Chief Financial Officer Daniel Calkins ha presentato un modulo Form 4 che segnala due vendite sul mercato aperto di azioni ordinarie Verastem:

  • 20/06/2025: 4.110 azioni vendute a 5,13 $ per azione.
  • 23/06/2025: 25 azioni vendute a 4,71 $ per azione.

La comunicazione spiega che le transazioni sono state eseguite esclusivamente per coprire gli obblighi fiscali derivanti dal consolidamento delle azioni vincolate (RSU) precedentemente assegnate. Non sono stati coinvolti strumenti derivati in questo rapporto.

Dopo le vendite, la proprietà diretta di Calkins ammonta a 109.945 azioni ordinarie. La cessione rappresenta circa il 3,6% delle sue partecipazioni dirette precedentemente dichiarate, lasciando l’esecutivo con una posizione azionaria significativa che continua ad allineare i suoi interessi con quelli degli azionisti.

Non sono stati comunicati ulteriori acquisti, esercizi di opzioni o nuove assegnazioni, né vi è indicazione di un piano di trading 10b5-1 per queste transazioni. Poiché le vendite sono state relativamente modeste e motivate da ragioni fiscali, l’impatto sul mercato è previsto limitato; tuttavia, gli investitori spesso monitorano l’attività degli insider per cogliere segnali di sentiment, e qualsiasi vendita da parte di un dirigente senior può attirare attenzione.

Verastem, Inc. (VSTM) � Resumen de transacciones internas Form 4

El Director Financiero Daniel Calkins presentó un Formulario 4 reportando dos ventas en el mercado abierto de acciones comunes de Verastem:

  • 20/06/2025: 4,110 acciones vendidas a $5.13 por acción.
  • 23/06/2025: 25 acciones vendidas a $4.71 por acción.

La presentación explica que las transacciones se realizaron únicamente para cubrir obligaciones fiscales legales derivadas de la consolidación de unidades restringidas de acciones (RSUs) previamente otorgadas. No se involucraron valores derivados en este informe.

Tras las ventas, la propiedad directa de Calkins asciende a 109,945 acciones comunes. La disposición representa aproximadamente el 3.6% de sus participaciones directas previamente reportadas, dejando al ejecutivo con una posición accionaria significativa que sigue alineando sus intereses con los de los accionistas.

No se divulgaron compras adicionales, ejercicios de opciones ni nuevas adjudicaciones, y no hay indicios de un plan de trading 10b5-1 para estas transacciones. Debido a que las ventas fueron relativamente pequeñas y se explicaron como relacionadas con impuestos, se espera que el impacto en el mercado sea limitado; sin embargo, los inversores suelen seguir la actividad de los insiders para obtener señales de sentimiento, y cualquier venta por parte de un alto ejecutivo puede atraer atención.

Verastem, Inc. (VSTM) � Form 4 내부� 거래 요약

최고재무책임�(CFO) 다니� 콜킨스가 Verastem 보통주에 대� � 건의 공개시장 매도� 보고하는 Form 4� 제출했습니다:

  • 2025� 6� 20�: 주당 $5.13� 4,110� 매도.
  • 2025� 6� 23�: 주당 $4.71� 25� 매도.

� 제출 서류� 이전� 부여된 제한 주식 단위(RSU)� 권리 확정으로 인해 발생� 법적 세금 원천징수 의무� 충당하기 위해 거래가 이루어졌음을 설명합니�. � 보고서에� 파생 증권� 포함되지 않았습니�.

매도 � 콜킨스의 직접 소유 지분은 109,945� 보통�입니�. 이번 매도� 이전� 보고� 직접 보유 지분의 � 3.6%� 해당하며, 경영진은 상당� 지분을 유지하며 주주들과 이해관계를 계속 일치시키� 있습니다.

추가 매수, 옵션 행사 또는 신규 수여� 공개되지 않았으며, � 거래� 대� 10b5-1 거래 계획� 없습니다. 매도가 비교� 적고 세금 관련임� 감안� � 시장 영향은 제한적일 것으� 예상되나, 투자자들은 종종 내부� 활동� 감정 신호� 주시하며, 고위 임원� 매도� 주목� 받을 � 있습니다.

Verastem, Inc. (VSTM) � Résumé des transactions d’initiés Formulaire 4

Le directeur financier Daniel Calkins a déposé un formulaire 4 rapportant deux ventes sur le marché libre d’actions ordinaires Verastem :

  • 20/06/2025 : 4 110 actions vendues à 5,13 $ par action.
  • 23/06/2025 : 25 actions vendues à 4,71 $ par action.

Le dépôt explique que ces transactions ont été effectuées uniquement pour couvrir les obligations fiscales légales déclenchées par l’acquisition des unités d’actions restreintes (RSU) précédemment attribuées. Aucun titre dérivé n’est concerné par ce rapport.

Après ces ventes, la propriété directe de M. Calkins s’élève à 109 945 actions ordinaires. La cession représente environ 3,6 % de ses avoirs directs précédemment déclarés, laissant le dirigeant avec une position significative en actions, ce qui continue d’aligner ses intérêts avec ceux des actionnaires.

Aucun achat supplémentaire, exercice d’options ou nouvelle attribution n’a été divulgué, et il n’y a aucune indication d’un plan de trading 10b5-1 pour ces transactions. Étant donné que les ventes sont relativement modestes et expliquées comme liées à des obligations fiscales, l’impact sur le marché devrait être limité ; toutefois, les investisseurs suivent souvent l’activité des initiés pour détecter des signaux de sentiment, et toute vente par un cadre supérieur peut attirer l’attention.

Verastem, Inc. (VSTM) � Zusammenfassung der Insider-Transaktionen Form 4

Finanzvorstand Daniel Calkins reichte ein Form 4 ein, das zwei Verkäufe von Verastem-Stammaktien am offenen Markt meldet:

  • 20.06.2025: 4.110 Aktien zu je 5,13 $ verkauft.
  • 23.06.2025: 25 Aktien zu je 4,71 $ verkauft.

Die Meldung erklärt, dass die Transaktionen ausschließlich zur Deckung gesetzlicher Steuerabzugsverpflichtungen erfolgten, die durch das Vesting zuvor gewährter Restricted Stock Units (RSUs) ausgelöst wurden. Es waren keine Derivate in diesem Bericht enthalten.

Nach den Verkäufen hält Calkins direkt 109.945 Stammaktien. Die Veräußerung entspricht etwa 3,6 % seiner zuvor gemeldeten direkten Beteiligungen und hinterlässt den Manager mit einer erheblichen Aktienposition, die seine Interessen weiterhin mit denen der Aktionäre in Einklang bringt.

Es wurden keine weiteren Käufe, Ausübungen von Optionen oder neue Zuteilungen bekannt gegeben, und es gibt keinen Hinweis auf einen 10b5-1-Handelsplan für diese Transaktionen. Da die Verkäufe relativ gering und steuerbedingt waren, wird die Marktwirkung als begrenzt eingeschätzt; dennoch verfolgen Investoren Insider-Aktivitäten oft als Stimmungsindikator, und jeder Verkauf durch einen leitenden Angestellten kann Aufmerksamkeit erregen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Calkins Daniel

(Last) (First) (Middle)
C/O VERASTEM, INC.,
117 KENDRICK ST., SUITE 500

(Street)
NEEDHAM MA 02494

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verastem, Inc. [ VSTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 S 4,110(1) D $5.13 109,945 D
Common Stock 06/23/2025 S 25(1) D $4.71 109,920 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
/s/ Daniel Calkin 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Verastem (VSTM) shares did CFO Daniel Calkins sell?

He sold 4,110 shares on 06/20/2025 and 25 shares on 06/23/2025, totaling 4,135 shares.

What was the average price of the shares sold by the Verastem CFO?

Shares were sold at $5.13 and $4.71; the weighted average is roughly $5.12 per share.

Why did the Verastem CFO sell shares according to the Form 4?

The filing states the sale was to satisfy statutory tax-withholding obligations resulting from RSU vesting.

How many Verastem shares does the CFO still own after the transaction?

Daniel Calkins now directly owns 109,945 common shares.

Does this Form 4 filing involve any derivative securities or option exercises?

No. No derivative transactions were reported in this Form 4.
Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

263.76M
49.81M
1.17%
76.29%
13.4%
Biotechnology
Pharmaceutical Preparations
United States
NEEDHAM